Global Large Volume Wearable Injectors Market 2017-2027 with Emphasis on the Emergence of Such Patient-Centric, Convenient, Cost-Effective and User-Friendly Wearable Injectors - Research and Markets
DUBLIN, Mar 03, 2017 /PRNewswire/ --
Research and Markets has announced the addition of the "Large Volume Wearable Injectors Market (3rd Edition), 2017-2027" report to their offering.
The "Large Volume Wearable Injectors Market (3rd Edition), 2017-2027" report features an extensive study of the current landscape and the likely future evolution of this category of drug delivery devices over the next ten years. With the increasing incidence of chronic and lifestyle-related diseases across the globe, the demand for efficient drug delivery systems is growing at a rapid pace.
It is worth noting that the VC community has demonstrated significant interest in funding projects related to such wearable injectors. These investments are expected to drive further innovation and lead to the introduction of novel device candidates in the industry. Quite recently, in January 2017, scPharmaceuticals closed a series B investment round worth USD 45.6 million.
The company intends to use the funding to bring Furoscix and the sc2Wear Infusor to the market in the US. Earlier, in July 2016, SteadyMed Therapeutics raised USD 32 million in a private placement round financed by Deerfield Capital Management, Federated Investors and OrbiMed. In September 2015, CeQur completed a USD 100 million Venture (Series C) financing round, which was led by Woodford Investment Management, Arthurian Life Sciences, Endeavour Vision, VI Partners and Schroders.
In order to simplify the process of drug delivery, eliminate costs and reduce the incidence of needlestick injuries, the pharmaceutical industry has shifted its focus towards the development of self-injection devices for parenteral drugs/therapies.
This report specifically lays emphasis on the emergence of such patient-centric, convenient, cost-effective and user-friendly wearable injectors that are capable of administering large volumes of a drug subcutaneously in a home-care setting.
It is worth noting that the concept behind such injectors is being widely employed for the delivery of insulin. Over 15 such unique series of injectors (excluding variants) have already entered the market. On the other hand, there is only one large volume wearable injector (mentioned above) approved for the administration of a non-insulin biologic in the US.
However, with a variety of biologics under investigation, we believe that device developers have a significant opportunity waiting to be tapped. The field is likely to pick up momentum in the next few years. In fact, an increase in the partnerships and investment activities demonstrate that the market is geared towards significant growth in the mid to long term.
One of the key objectives outlined for the study was to evaluate the future potential of the ongoing development programs of both big and small firms.
Key Topics Covered:
1. Preface
2. Executive Summary
3. Introduction
4. Large Volume Wearable Injectors: Market Landscape
5. Product Competitiveness, Clinical Design And Patent Analysis
6. Large Volume Wearable Injectors For Non-Insulin Biologics: Device Profiles
7. Large Volume Wearable Injectors For Insulin: Device Profiles
8. Case Studies: Drug-Device Combinations Under Evaluation
9. Target Biologics For Large Volume Wearable Injectors
10. Market Forecast And Opportunity Analysis
11. Large Volume Wearable Injectors: Key Players
12. Swot Analysis
13. Conclusion
14. Interview Transcripts
15. Appendix 1: Tabulated Data
16. Appendix 2: List Of Companies And Organizations
- 5AM Ventures
- ARTORG Center for Biomedical Research
- AVEO Oncology
- AbGenomics
- AbbVie
- Abbott Laboratories
- Ablynx
- Acceleron Pharma
- Accord Healthcare
- Aduro Biotech
- Advaxis
- Agenus
- AgonOx
- Akorn
- Alder BioPharmaceuticals
- Alexion Pharmaceuticals
- Alixinox Pharmaceuticals
- Alnylam Pharmaceuticals
- AlphaCore Pharma
- Altor BioScience
- Alzheimer's Association
- American Academy of Neurology
- American Nurses Association
- Amgen
- Amphastar Pharmaceuticals
- Animas Corporation
- Antares Pharma
- Antigen Express
- Apotex
- Arbutus Biopharma
- Argos Therapeutics
- Arteaus Therapeutics
- Arthurian Life Sciences
- Asante Solutions
- Aspen Pharmacare
- Astellas Pharma
- Asthma and Allergy Foundation of America
- AstraZeneca
- Athersys
- Aurum Pharmaceuticals
- Banque
- Bar Ilan University
- Bardy Diagnostics
- Baxter
- Bayer
- Bayhill Therapeutics
- Becton Dickinson
- Bern University Hospital
- Bespak
- Bigfoot Biomedical
- Bio-Path Holdings
- BioArctic Neuroscience
- BioCSL
- BioInvent International
- BioMarin Pharmaceutical
- Biogen
- Bioject Medical Technologies
- Biotest
- Boehringer Ingelheim
- Bristol-Myers Squibb
- CANÈ
- CEL-SCI Corporation
- CONNECT
- CROSSJECT
- CSL Behring
- Cala Health
- Calando Pharmaceuticals
- Cam Med
- Canadian Institute for Health Information
- Canadian Intellectual Property Office
- Cancer Advances
- Cardiome Pharma
- Catalyst Biosciences
- CeQur
- Celgene
- Celldex Therapeutics
- Cellerant Therapeutics
- Cellnovo
- Centers for Disease Control and Prevention
- Chugai Pharmaceutical
- Cincinnati Children's Hospital Medical Center
- Cipla
- Circadian Technologies
- Cleveland BioLabs
- Consort Medical
- Crealta Pharmaceuticals
- CureTech
- CytoDyn
- Cytonet
- DEKA
- Daikyo Seiko
- Debiotech
- Deerfield Management Company
- Dekkun
- Denderon
- Dexcom
- Diamyd Medical
- Diasend
- Duke University Medical Center
- EMD Serono
- Egalet Corporation
- Eisai
- Elan Pharmaceuticals
- Elcam Drug Delivery Devices
- Eli Lilly
- Elias Group
- Elusys Therapeutics
- Emcure Pharmaceuticals
- Emergent BioSolutions
- Emory University Hospital
- Enable Injections
- Endeavour Vision
- Endo Pharmaceuticals
- Endocyte
- Eternity Healthcare
- European Agency of Occupational Safety and Health
- European Pharma Group
- Federated Investors
- Ferring Pharmaceuticals
- FibroGen
- Finox Biotech
- Five Prime Therapeutics
- Flex (formerly Flextronix)
- Flowonix Medical
- Forma Medical Device Design
- Fresenius Kabi
- Galaxy Biotech
- Galena Biopharma
- Genentech
- Generon Corporation (Shanghai)
- Geno Pharmaceuticals
- Genzyme Corporation
- Gilead Sciences
- Gland Pharma
- GlaxoSmithKline
- Gliknik
- Glooko
- Halozyme Therapeutics
- HanAll BioPharma
- Hanmi Pharmaceutical
- HealthPrize Technologies
- Heart Failure Clinical Research Network
- Heart Failure Society of America
- Hemispherx Biopharma
- Hospira
- INJEX Pharma
- IP Holdings
- iSense CGM
- ImClone Systems
- Immatics Biotechnologies
- Immune Response BioPharma
- ImmunoFrontier
- ImmunoGen
- Immunocore
- Immunomedics
- Immunotope
- Immunovaccine
- Immunovative Therapies
- Ind-Swift
- Ingenus Pharmaceuticals
- Inovio Pharmaceuticals
- Insulet Corporation
- Insuline Medical
- International Diabetes Federation
- Ionis Pharmaceuticals
- Ipca Laboratories
- Ipsen
- Janssen Biotech
- Johnson & Johnson
- KB Partners
- KaloBios Pharmaceuticals
- Kaléo
- Kyowa Hakko Kirin
- Leading Pharma
- LifeScan
- Lundbeckfonden Ventures
- MEDAXOR
- MENTRIK Biotech
- MabVax Therapeutics
- MacroGenics
- Massachusetts General Hospital
- Mayo Clinic
- MedImmune
- Medical International Technology
- Medicom Innovation Partner
- Medicus Engineering
- Medimop Medical Projects
- Medipacs
- Medtronic
- Medtrum
- Merck
- Meridian Medical Technologies
- Merrimack Pharmaceuticals
- Merz Pharma
- MetroHealth System
- Mode AGC
- Modi Mundi Pharma
- MolMed
- MorphoSys
- Morphotek
- Mylan
- National Institute for Clinical Excellence
- National Institutes of Health
- Neogenix Oncology
- Neon Laboratories
- NeuroDerm
- Noble
- Norwich Pharmaceuticals
- Novartis
- Novo Nordisk
- Nuron Biotech
- ORI Healthcare Fund
- Occupational Safety and Health Administration
- Octapharma
- Omeros
- OncoGenex Pharmaceuticals
- OncoMed Pharmaceuticals
- OncoPep
- Optimer Pharmaceuticals
- OrbiMed
- Otsuka Pharmaceutical
- Owen Mumford
- Peregrine Pharmaceuticals
- Perqflo
- Pfizer
- PharmaJet
- PhaseBio Pharmaceuticals
- Pico Life Technologies
- PicoSulin
- Pique Therapeutics
- Pliva
- Pluristem Therapeutics
- Polaris Pharmaceuticals
- Polynoma
- Portola Pharmaceuticals
- Prachi Pharmaceuticals
- Progenics Pharmaceuticals
- Promethera Biosciences
- Prometheus Laboratories
- Protalix BioTherapeutics
- Qualitest Pharmaceuticals
- Quest Pharmatech
- Quintessence Biosciences
- RAD BioMed
- rEVO Biologics
- Ranbaxy Laboratories
- Ratio Drug Delivery
- Regeneron Pharmaceuticals
- Roche
- Roehr Products
- Roxane Laboratories
- SBIR Healthcare
- SOOIL
- STMicroelectronics
- Sagent Pharmaceuticals
- Salix Pharmaceuticals
- Samson Ventures Partners
- Sandoz
- Sangamo BioSciences
- Sanofi
- Sarpeta Therapeutics
- ScPharmaceuticals
- Schroders
- SciGen
- Seattle Genetics
- Sensile Medical
- Shionogi
- Shire
- Sigma-Tau Pharmaceuticals
- SillaJen BioTherapeutics
- SteadyMed Therapeutics
- Stemline Therapeutics
- Sun Pharmaceutical Industries
- Sunovion Pharmaceuticals
- Syntax Corporation
- TG Therapeutics
- TRACON Pharmaceuticals
- TaiMed Biologics
- Takeda Pharmaceutical Company
- Tamir Biotechnology
- Tandem Diabetes Care
- Teva Pharmaceutical Industries
- The Tech Group
- Tidepool
- Touche Medical
- TypeZero Technologies
- UCB
- US WorldMeds
- Unilife Corporation
- United Biomedical
- United States Patent and Trademark Office
- United Therapeutics
- University of Bern
- VBL Therapeutics
- VI Partners
- Vaccinex
- Vaccinogen
- Valeritas
- Valtronic
- ViCentra
- Vintage Pharmaceuticals
- West Pharmaceutical Services
- Wockhardt
- Woodford Investment Management
- World Intellectual Property Organization
- XBiotech
- XOMA Corporation
- Xencor
- YOFimeter
- Ypsomed
For more information about this report visit http://www.researchandmarkets.com/research/4ccrs6/large_volume
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Share this article